EP0602069A4 - Retrovirase protease inhibitoren. - Google Patents
Retrovirase protease inhibitoren.Info
- Publication number
- EP0602069A4 EP0602069A4 EP92917238A EP92917238A EP0602069A4 EP 0602069 A4 EP0602069 A4 EP 0602069A4 EP 92917238 A EP92917238 A EP 92917238A EP 92917238 A EP92917238 A EP 92917238A EP 0602069 A4 EP0602069 A4 EP 0602069A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- protease inhibitors
- retroviral protease
- retroviral
- inhibitors
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/95—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by nitrogen atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73156391A | 1991-07-17 | 1991-07-17 | |
| US731563 | 1991-07-17 | ||
| US87097592A | 1992-04-20 | 1992-04-20 | |
| US870975 | 1992-04-20 | ||
| PCT/US1992/006047 WO1993002057A1 (en) | 1991-07-17 | 1992-07-17 | Retroviral protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0602069A1 EP0602069A1 (de) | 1994-06-22 |
| EP0602069A4 true EP0602069A4 (de) | 1995-05-03 |
Family
ID=27112266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP92917238A Withdrawn EP0602069A4 (de) | 1991-07-17 | 1992-07-17 | Retrovirase protease inhibitoren. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0602069A4 (de) |
| JP (1) | JPH07500577A (de) |
| AP (1) | AP9200410A0 (de) |
| AU (1) | AU2412992A (de) |
| CA (1) | CA2113644A1 (de) |
| IE (1) | IE922316A1 (de) |
| IL (1) | IL102534A0 (de) |
| MX (1) | MX9204233A (de) |
| PT (1) | PT100704A (de) |
| WO (1) | WO1993002057A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
| US5888992A (en) * | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
| MXPA93002392A (es) | 1992-03-11 | 2005-02-04 | Narhex Ltd | Derivados amino de hidrocarburos-oxo e hidroxi-substituidos. |
| US6071895A (en) * | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
| JPH07504654A (ja) * | 1992-03-11 | 1995-05-25 | ナルヘックス リミテッド | オキソ及びヒドロキシ置換炭化水素のアミン誘導体 |
| GB9207380D0 (en) * | 1992-04-03 | 1992-05-13 | Ici Plc | Compounds |
| US5559256A (en) * | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
| ES2068739B1 (es) * | 1993-01-21 | 1995-11-01 | Smithkline Beecham Corp | Inhibidores retrovirables de proteasas. |
| IL110898A0 (en) * | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
| US5932550A (en) * | 1995-06-30 | 1999-08-03 | Japan Energy Corporation | Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof |
| US6222043B1 (en) | 1995-06-30 | 2001-04-24 | Japan Energy Corporation | Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof |
| US5965532A (en) * | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
| US6291432B1 (en) | 1996-12-27 | 2001-09-18 | Japan Energy Corporation | Tripeptide compounds and anti-AIDS medicine |
| KR100447553B1 (ko) | 1997-02-26 | 2004-09-08 | 화이자 인코포레이티드 | 헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 ｍｉｐ-1 알파의 ｃｃｒ1 수용체로의 결합에 대한 선택적 저해제로서의 용도 |
| US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
| US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
| CA2304206A1 (en) | 1997-09-29 | 1999-04-08 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
| CA2331122A1 (en) | 1998-05-04 | 1999-11-11 | Point Therapeutics, Inc. | Hematopoietic stimulation |
| AU765370B2 (en) | 1998-06-05 | 2003-09-18 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| DE60124080T2 (de) | 2000-03-23 | 2007-03-01 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| EP1299352B1 (de) | 2000-06-30 | 2005-12-28 | Elan Pharmaceuticals, Inc. | Verbindungen zur behandlung der alzheimerischen krankheit |
| EP1666452A2 (de) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Verbindungen zur Behandlung der Alzheimerischen Krankheit |
| EP1401452A1 (de) | 2001-06-27 | 2004-03-31 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamin-derivate zur behandlung von alzheimer krankheit |
| UY30805A1 (es) * | 2006-12-21 | 2008-07-31 | Bayer Schering Pharma Ag | Moduladores no esteroides de receptores de progesterona |
| CN112888677A (zh) | 2018-08-16 | 2021-06-01 | 先天肿瘤免疫公司 | 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法 |
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| CN114605320B (zh) * | 2022-04-06 | 2023-12-29 | 南京艾康生物科技有限公司 | 一种5-硝基-6-甲基烟酸乙酯的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0486948A2 (de) * | 1990-11-20 | 1992-05-27 | Abbott Laboratories | Inhibitoren retroviraler Proteasen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431653A (en) * | 1982-03-18 | 1984-02-14 | Hoffmann-La Roche Inc. | Penicillanic acid derivatives |
-
1992
- 1992-07-16 IE IE231692A patent/IE922316A1/en not_active Application Discontinuation
- 1992-07-17 EP EP92917238A patent/EP0602069A4/de not_active Withdrawn
- 1992-07-17 PT PT100704A patent/PT100704A/pt not_active Application Discontinuation
- 1992-07-17 MX MX9204233A patent/MX9204233A/es unknown
- 1992-07-17 CA CA002113644A patent/CA2113644A1/en not_active Abandoned
- 1992-07-17 IL IL102534A patent/IL102534A0/xx unknown
- 1992-07-17 WO PCT/US1992/006047 patent/WO1993002057A1/en not_active Ceased
- 1992-07-17 AP APAP/P/1992/000410A patent/AP9200410A0/en unknown
- 1992-07-17 AU AU24129/92A patent/AU2412992A/en not_active Abandoned
- 1992-07-17 JP JP5503016A patent/JPH07500577A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0486948A2 (de) * | 1990-11-20 | 1992-05-27 | Abbott Laboratories | Inhibitoren retroviraler Proteasen |
Also Published As
| Publication number | Publication date |
|---|---|
| AP9200410A0 (en) | 1992-07-31 |
| WO1993002057A1 (en) | 1993-02-04 |
| AU2412992A (en) | 1993-02-23 |
| MX9204233A (es) | 1994-06-30 |
| JPH07500577A (ja) | 1995-01-19 |
| CA2113644A1 (en) | 1993-02-04 |
| IL102534A0 (en) | 1993-01-14 |
| EP0602069A1 (de) | 1994-06-22 |
| PT100704A (pt) | 1993-10-29 |
| IE922316A1 (en) | 1993-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0602069A4 (de) | Retrovirase protease inhibitoren. | |
| MX9100119A (es) | Inhibidores de proteasa retroviral | |
| FI915819L (fi) | Hiv- proteas-inhibitorer. | |
| FI950650L (fi) | Retrovirusproteaasi-inhibiittoreina käyttökelpoisia hydroksietyyliaminosulfoniamideja | |
| FI950651L (fi) | Retrovirusproteaasi-inhibiittoreina käyttökelpoisia sulfonyylialkanoyyliaminohydroksietyyliaminosulfoniamideja | |
| MA24298A1 (fr) | Inhibiteurs de protease. | |
| DK0722439T3 (da) | HIV-proteaseinhibitorer | |
| FI933277A7 (fi) | Amiinidioli proteaasi-inhibiittorit | |
| FI913788A7 (fi) | Seriiniproteaasien inhibiittoreita | |
| MX9102311A (es) | Inhibidores de proteasa de vih. | |
| FI904101A0 (fi) | 17b-acyl-4-aza-5a-androst-1-en-3-on- som 5a-reduktasinhibitorer. | |
| FI935644A7 (fi) | Retrovirusten proteaasi-inhibiittoreita | |
| FI962488L (fi) | HIV:n proteaasin inhibiittoreita | |
| NO895026D0 (no) | Retrovirale proteasehemmere. | |
| MX9100120A (es) | Inhibidores de proteasas retrovirales | |
| EP0628035A4 (de) | Retrovirale protease inhibitoren. | |
| MX9206568A (es) | Derivados de sacarina inhibidores de enzimas proteoliticas. | |
| FI906140A7 (fi) | Retroviraalisten proteaasien inhibiittoreita | |
| DE68922014D1 (de) | Protease. | |
| EP0566237A3 (de) | Inhibitoren der retroviralen Protease. | |
| NO975534L (no) | Imidazo-£1,5|-pyridin-avledete serinproteaseinhibitorer | |
| MX22596A (es) | Inhibidores de proteasas retrovirales. | |
| FI940647A7 (fi) | Parannetut erittäin alkaliset proteaasit | |
| MX9204259A (es) | Compuestos inhibidores de proteasa retroviral. | |
| ZA925360B (en) | Retroviral protease inhibitors. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19940125 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
| A4 | Supplementary search report drawn up and despatched | ||
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE FR GB IT LI NL |
|
| 17Q | First examination report despatched |
Effective date: 19971125 |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19980806 |